Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03183141
Other study ID # SERES-013
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 23, 2017
Est. completion date April 29, 2022

Study information

Verified date April 2023
Source Seres Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cohort 1: Subjects who had a Clostridioides difficile infection (CDI) recurrence in study SERES-012 within 8 weeks of receipt of study drug will be eligible. The purpose of this cohort is to assess safety and efficacy of SER-109 in reducing recurrence of CDI in adults who had a CDI recurrence within 8 weeks after receipt of SER-109 or Placebo in study SERES-012. Cohort 2: Cohort 2 is an open-label program for subjects who were not part of SERES-012. The purpose of this cohort is to describe safety and tolerability of SER-109 in subjects 18 years of age or older with at least a first recurrence of CDI.


Description:

Cohort 1 is an open-label extension of study SERES-012. Subjects who had a CDI recurrence in study SERES-012 within 8 weeks of receipt of study drug, have responded to a course of standard of care (SOC) antibiotic treatment, will receive an oral dose of SER-109. A treatment regimen of SER-109 is defined as an oral dose of SER-109 (4 capsules once daily) for 3 consecutive days. Approximately 30 eligible subjects with recurrent CDI disease from study SERES-012 are expected to enroll. Screening for this study will begin at the Recurrence Visit of Study SERES-012. Cohort 2 is an open-label program for subjects who were not part of SERES-012. Subjects 18 years of age or older who had one or more CDI recurrence and have responded to a course of antibiotic treatment will receive an oral dose of SER-109. The CDI recurrence must be confirmed by a positive C. difficile stool toxin or polymerase chain reaction (PCR) assay to confirm eligibility. A treatment regimen of SER-109 is defined as an oral dose of SER-109 (4 capsules once daily) for 3 consecutive days. Approximately 200 eligible subjects with recurrent CDI disease are expected to enroll.


Recruitment information / eligibility

Status Completed
Enrollment 263
Est. completion date April 29, 2022
Est. primary completion date April 29, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Cohort 1 Main Inclusion Criteria: 1. Previously enrolled in Study SERES-012, had CDI recurrence within 8 weeks after receipt of a treatment regimen of SER-109 or placebo 2. Signed informed consent prior to initiation of any study-specific procedure or treatment. The subject, or their legally authorized representative, must be able to provide written informed consent and understand the potential risks and benefits from study enrollment and treatment. 3. The CDI recurrence in Study SERES-012 must have met the protocol definition of = 3 unformed stools per day over 2 consecutive days, a positive C. difficile stool toxin assay, and the requirement of CDI SOC antibiotic therapy, and an adequate clinical response following antibiotic therapy (<3 unformed stools in 24 hours for 2 or more consecutive days). Cohort 1 Main Exclusion Criteria: 1. Female subjects who are pregnant, breastfeeding, lactating, or planning to become pregnant during the study. 2. Known or suspected toxic megacolon and/or known small bowel ileus. 3. Admitted to or expected to be admitted to an intensive care unit for medical reasons (not just boarding). Note: nursing homes, rehabilitation, assisted living centers and acute care hospitals are acceptable. 4. Absolute neutrophil count of <500 cells/mm^3. 5. Major gastrointestinal surgery (e.g. significant bowel resection or diversion) within 3 months before enrollment (this does not include appendectomy or cholecystectomy), or any history of total colectomy or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e., restrictive procedures such as banding, are permitted). 6. History of active inflammatory bowel disease (ulcerative colitis, Crohn's disease, microscopic colitis) with diarrhea believed to be caused by active inflammatory bowel disease in the past 3 months. 7. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy (subjects on maintenance chemotherapy may only be enrolled after consultation with the study medical monitor). 8. Any history of fecal microbiota transplantation (FMT) in the past 3 months. Cohort 2 Main Inclusion Criteria: 1. Subjects 18 years of age or older who had one or more CDI recurrence (as confirmed by a C. difficile stool toxin or PCR test) and have responded to a course of antibiotic treatment. 2. Signed informed consent prior to initiation of any study-specific procedure or treatment. The subject, or their legally authorized representative, must be able to provide written informed consent and understand the potential risks and benefits from study enrollment and treatment. Cohort 2 Main Exclusion Criteria: (all Cohort 1 exclusion criteria [#1-8 above] plus the below addition criterion) 9. Previously enrolled in a Seres Therapeutics clinical study. An exception is made for subjects who screened in SERES-012 who did not receive SER-109 and did not previously roll-over to SERES-013.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
SER-109
SER-109, an oral, biologically derived, live microbiome therapeutic that comprises purified bacterial spores

Locations

Country Name City State
Canada (Investigator site) Calgary Alberta
Canada (Investigator site) Chicoutimi Quebec
Canada (Investigator site) London Ontario
Canada (Investigator site) North Bay Ontario
Canada (Investigator site) Québec Quebec
Canada (Investigator site) Saint John's Newfoundland and Labrador
Canada (Investigator site) Sainte-Foy Quebec
Canada (Investigator site) Scarborough Ontario
Canada (Investigator site) Vancouver British Columbia
Canada (Investigator site) Victoria British Columbia
United States (Investigator site) Akron Ohio
United States (Investigator site) Annapolis Maryland
United States (Investigator site) Athens Georgia
United States (Investigator site) Atlanta Georgia
United States (Investigator site) Boise Idaho
United States (Investigator site) Boston Massachusetts
United States (Investigator site) Buffalo New York
United States (Investigator site) Butte Montana
United States (Investigator site) Camp Hill Pennsylvania
United States (Investigator site) Centerville Ohio
United States (Investigator site) Charlotte North Carolina
United States (Investigator site) Chesterfield Missouri
United States (Investigator site) Chesterfield Michigan
United States (Investigator site) Chevy Chase Maryland
United States (Investigator site) Chicago Illinois
United States (Investigator site) Cincinnati Ohio
United States (Investigator site) Clearwater Florida
United States (Investigator site) Clearwater Florida
United States (Investigator site) Cleveland Ohio
United States (Investigator site) Cypress Texas
United States (Investigator site) Decatur Georgia
United States (Investigator site) DeLand Florida
United States (Investigator site) Detroit Michigan
United States (Investigator site) Dothan Alabama
United States (Investigator site) Evansville Indiana
United States (Investigator site) Flint Michigan
United States (Investigator site) Framingham Massachusetts
United States (Investigator site) Garland Texas
United States (Investigator site) Glen Burnie Maryland
United States (Investigator site) Greenville North Carolina
United States (Investigator site) Harrisburg Pennsylvania
United States (Investigator site) Hialeah Florida
United States (Investigator site) Homestead Florida
United States (Investigator site) Houston Texas
United States (Investigator site) Houston Texas
United States (Investigator site) Houston Texas
United States (Investigator site) Houston Texas
United States (Investigator site) Idaho Falls Idaho
United States (Investigator site) Iowa City Iowa
United States (Investigator site) Jacksonville Florida
United States (Investigator site) Jacksonville North Carolina
United States (Investigator site) Kansas City Kansas
United States (Investigator site) Kinston North Carolina
United States (Investigator site) Marietta Georgia
United States (Investigator site) Mather California
United States (Investigator site) McKinney Texas
United States (Investigator site) Mentor Ohio
United States (Investigator site) Miami Florida
United States (Investigator site) Miami Florida
United States (Investigator site) Miami Florida
United States (Investigator site) Miami Florida
United States (Investigator site) Miami Florida
United States (Investigator site) Miami Florida
United States (Investigator site) Miami Lakes Florida
United States (Investigator site) Milwaukee Wisconsin
United States (Investigator site) Morristown New Jersey
United States (Investigator site) Morrow Georgia
United States (Investigator site) Mountain View California
United States (Investigator site) Murrieta California
United States (Investigator site) Naples Florida
United States (Investigator site) Neptune New Jersey
United States (Investigator site) New Orleans Louisiana
United States (Investigator site) New York New York
United States (Investigator site) North Dartmouth Massachusetts
United States (Investigator site) Northridge California
United States (Investigator site) Oak Lawn Illinois
United States (Investigator site) Ogden Utah
United States (Investigator site) Orlando Florida
United States (Investigator site) Pasadena Texas
United States (Investigator site) Pembroke Pines Florida
United States (Investigator site) Pembroke Pines Florida
United States (Investigator site) Pittsburgh Pennsylvania
United States (Investigator site) Port Orange Florida
United States (Investigator site) Providence Rhode Island
United States (Investigator site) Riverton Utah
United States (Investigator site) Rochester Minnesota
United States (Investigator site) Royal Oak Michigan
United States (Investigator site) Sacramento California
United States (Investigator site) Salt Lake City Utah
United States (Investigator site) San Antonio Texas
United States (Investigator site) San Bernardino California
United States (Investigator site) San Diego California
United States (Investigator site) San Dimas California
United States (Investigator site) Sayre Pennsylvania
United States (Investigator site) Simi Valley California
United States (Investigator site) Southlake Texas
United States (Investigator site) Spokane Washington
United States (Investigator site) Spring Texas
United States (Investigator site) Springfield Illinois
United States (Investigator site) Sun City West Arizona
United States (Investigator site) Tacoma Washington
United States (Investigator site) Thousand Oaks California
United States (Investigator site) Toledo Ohio
United States (Investigator site) Union City Tennessee
United States (Investigator site) Weymouth Massachusetts
United States (Investigator site) Worcester Massachusetts
United States (Investigator site) Wyoming Michigan

Sponsors (1)

Lead Sponsor Collaborator
Seres Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cohort 1: Recurrence of CDI and Sustained Clinical Response Cohort 1: Recurrence of CDI up to 8 Weeks after treatment. Recurrence was determined by stool Clostridioides difficile toxin assay. Sustained clinical response was the absence of CDI recurrence up to 8 Weeks after treatment. Up to Week 8
Primary Cohort 2: Recurrence of CDI and Sustained Clinical Response Cohort 2: Recurrence of CDI up to 8 and 12 Weeks after treatment. Recurrence was determined by stool Clostridioides difficile toxin assay. Sustained clinical response was the absence of CDI recurrence up to 8 and 12 Weeks after treatment. Up to Weeks 8 and 12
See also
  Status Clinical Trial Phase
Recruiting NCT03895593 - Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
Withdrawn NCT04679324 - The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection
Completed NCT04675723 - The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
Recruiting NCT05693077 - Clostridioides Difficile Colonisation Phase 1
Completed NCT04668014 - The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection
Recruiting NCT05709184 - Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection N/A
Terminated NCT05526807 - Ursodeoxycholic Acid in C. Difficile Infection N/A
Recruiting NCT06306014 - Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients Phase 1/Phase 2
Recruiting NCT06237452 - VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3
Terminated NCT04802837 - Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects Phase 3
Active, not recruiting NCT04885946 - Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection N/A
Recruiting NCT04305769 - Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) Phase 2
Recruiting NCT06106698 - Washed Microbiota Transplantation for Clostridioides Difficile Infection
Active, not recruiting NCT04781387 - Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection Phase 2
Completed NCT03595566 - To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Phase 3
Completed NCT03595553 - Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Phase 3
Completed NCT04725123 - Addressing Personalized Needs in Clostridioides Difficile Infection N/A
Not yet recruiting NCT05852587 - Xylitol Use for Decolonization of C. Difficile in Patients With IBD Phase 1
Completed NCT03788434 - Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 2
Recruiting NCT05612672 - Evaluation of GeoHAI Implementation N/A